Monte Rosa Therapeutics (GLUE) filed a registration statement Thursday for the potential sale of up to $400 million of various securities.
The prospectus covers the sale of the company's debt securities, common stock, preferred stock, units and warrants from time to time.
Monte Rosa said it intends to use the net proceeds from the sale of any securities for general corporate purposes, which may include research and development and clinical development costs to support the advancement of its product candidates and the expansion of its research and development programs.
Price: 7.20, Change: +0.50, Percent Change: +7.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.